S-1: TransCode Therapeutics Eyes $7.5 Million Capital Infusion Through Stock and Warrant Offering

TransCode Therapeutics is seeking to raise up to $7.5 million through a public offering of common stock and warrants to advance its oncology-focused RNA therapeutic programs.

Summary

• TransCode Therapeutics is offering up to 1,266,892 shares of common stock along with warrants to purchase an equal number of shares.
• The offering also includes pre-funded warrants as an alternative for investors who would exceed ownership limits.
• The assumed public offering price is $5.92 per share and accompanying warrant, based on the closing price on January 5, 2024, adjusted for a planned reverse stock split.
• The company intends to use the net proceeds for product development activities, including clinical trials of TTX-MC138, and for working capital.
• TransCode estimates that the net proceeds from this offering, along with existing funds, will satisfy capital needs for approximately the next eight months, assuming gross proceeds of $7.5 million.
• The offering is being conducted on a 'best efforts' basis with no minimum offering amount required.
• The offering is expected to close around January , 2024.
• The company's stock is currently listed on the Nasdaq Capital Market under the symbol RNAZ, but the company is not in compliance with Nasdaq's stockholders' equity requirement and may be delisted.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential of the company's technology and clinical programs, it also acknowledges significant financial challenges and risks, including the need for additional funding and the possibility of delisting from the Nasdaq Capital Market. The overall tone is cautiously optimistic, but the financial uncertainties weigh heavily on the sentiment.

Positives

• The company is actively pursuing funding to advance its clinical programs.
• The company has a lead therapeutic candidate, TTX-MC138, in clinical development.
• The company has received authorization from the FDA to conduct a Phase 0 clinical trial.
• The company has a proprietary delivery platform, TTX, designed to improve outcomes for cancer patients.
• The company has received Orphan Drug Designation from the FDA for TTX-MC138 for pancreatic cancer.

Negatives

• The company has a history of net losses and expects to continue incurring losses.
• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• The company is at risk of being delisted from the Nasdaq Capital Market.
• The company is dependent on the success of TTX-MC138, which is in the early stages of development.
• The company relies on third-parties for manufacturing and clinical trials.

Risks

• The company's low cash position and need for additional capital raise substantial doubt about its ability to continue operations.
• The company's business is highly dependent on the success of TTX-MC138, which is at the early stages of development.
• A potential delisting of the company's common stock from trading on the Nasdaq Capital Market.
• The results and timing of the company's preclinical and clinical trial activities are uncertain.
• The company's ability to expand its therapeutic candidate portfolio is uncertain.
• The company's ability to receive regulatory approval for its therapeutic candidates is uncertain.
• The company relies on third-parties for the planning, conduct and monitoring of clinical trials, for the manufacture of clinical drug supplies and drug product and for other requirements.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than the company does.
• The price of the company's common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of the company's common stock.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to file an IND application with the FDA in the first quarter of 2024 seeking approval to conduct a Phase 1/II clinical trial with TTX-MC138 in patients with advanced solid tumors.

Industry Context

The global metastatic cancer treatment market is expected to reach $136.9 billion by 2032, highlighting the significant unmet medical need and market opportunity.

Comparison to Industry Standards

• The document mentions competitors such as Ionis, Moderna, Alnylam, BioNTech, Dicerna, and Siranomics, which have therapeutic candidates in various stages of preclinical and clinical developments.
• Arrowhead Pharmaceuticals is also mentioned as a clinical stage company with a pipeline of investigational RNAi therapeutics.
• The document highlights that TransCode's TTX delivery platform is differentiated from competitive delivery approaches, many of which rely on lipid particles or chemical structures, such as GalNAc, which effectively target sites in the liver but not sites in tumors and metastases elsewhere.
• The document also mentions that TransCode's TTX nanocarrier is derived from, and is chemically similar to, nanoparticles extensively used in imaging (Feridex, from Advanced Magnetics) or for treating iron deficiency anemia (Feraheme, also from Advanced Magnetics).

Stakeholder Impact

• Shareholders may experience dilution in the net tangible book value of the shares purchased in the offering.
• Shareholders may experience volatility in the price of the company's common stock.
• Employees may be affected by the company's restructuring and cost reduction measures.
• The company's ability to develop and commercialize its therapeutic candidates will impact patients with cancer.

Next Steps

• Enroll additional patients in the Phase 0 trial.
• Submit the IND application for the Phase I clinical trial in the first quarter of 2024.
• Complete assay development to measure miR-10b in blood samples from patients in the Phase I trial.
• Complete a partnering agreement with respect to one or more therapeutic candidates sometime in 2024.
• Initiate manufacturing activities to support IND-enabling studies for other preclinical assets if capital is available in 2024.
• File for European Orphan Drug Designation status for TTX-MC138 in pancreatic cancer in 2024.

Key Dates

Keywords

TTX-MC138, clinical trials, warrants, common stock, pre-funded warrants, oncology, RNA therapeutics, metastatic cancer, capital raise, FDA, biotechnology